Racial and Ethnic Disparities and Facility-Level Variation in GLP-1 RA Prescription among US Veterans with CKD.
作者信息
Gregg L Parker, Worsley Melandrea L, Ramsey David J, Segar Matthew W, Matheny Michael E, Virani Salim S, Navaneethan Sankar D
机构信息
Section of Nephrology , Baylor College of Medicine , Selzman Institute for Kidney Health , Houston , Texas.
Research Service Line , Michael E. DeBakey Veterans Affairs Medical Center , Houston , Texas.
出版信息
Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1479-1482. doi: 10.2215/CJN.0000000000000266. Epub 2023 Jul 25.
Abstract
摘要
相似文献
1
Racial and Ethnic Disparities and Facility-Level Variation in GLP-1 RA Prescription among US Veterans with CKD.美国慢性肾脏病退伍军人中GLP-1受体激动剂处方的种族和民族差异以及机构层面的差异
Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1479-1482. doi: 10.2215/CJN.0000000000000266. Epub 2023 Jul 25.
2
Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.在美国退伍军人事务部医疗体系中，2 型糖尿病患者种族和民族与 SGLT2 抑制剂和 GLP1 受体激动剂处方的相关性。
JAMA. 2022 Sep 6;328(9):861-871. doi: 10.1001/jama.2022.13885.
3
Racial and Ethnic Health Care Disparities Among Women in the Veterans Affairs Healthcare System: A Systematic Review.退伍军人事务医疗系统中女性的种族和族裔医疗保健差异：一项系统综述。
Womens Health Issues. 2016 Jul-Aug;26(4):401-9. doi: 10.1016/j.whi.2016.03.009. Epub 2016 Apr 29.
4
Trends in Chronic Kidney Disease Care in the US by Race and Ethnicity, 2012-2019.2012-2019 年美国按种族和民族划分的慢性肾脏病护理趋势。
JAMA Netw Open. 2021 Sep 1;4(9):e2127014. doi: 10.1001/jamanetworkopen.2021.27014.
5
Trends in Racial and Ethnic Disparities in Early Glycemic Control Among Veterans Receiving Care in the Veterans Health Administration, 2008-2019.2008-2019 年，在退伍军人健康管理局接受治疗的退伍军人中，血糖控制早期的种族和民族差异趋势。
Diabetes Care. 2024 Nov 1;47(11):1978-1984. doi: 10.2337/dc24-0892.
6
Mortality Disparities in Racial/Ethnic Minority Groups in the Veterans Health Administration: An Evidence Review and Map.退伍军人事务部中少数族裔群体的死亡率差异：证据综述和地图。
Am J Public Health. 2018 Mar;108(3):e1-e11. doi: 10.2105/AJPH.2017.304246.
7
Diagnosis and treatment patterns of Peyronie's disease among different racial, ethnic, and regional groups in the Veterans Affairs healthcare system.退伍军人事务部医疗保健系统中不同种族、民族和地区群体的佩罗尼病的诊断和治疗模式。
Int J Impot Res. 2023 Dec;35(8):706-711. doi: 10.1038/s41443-022-00615-y. Epub 2022 Sep 23.
8
Patterns of sex and racial/ethnic differences in patient health care experiences in US Veterans Affairs hospitals.美国退伍军人事务医院中患者医疗体验的性别和种族/民族差异模式。
Med Care. 2014 Apr;52(4):328-35. doi: 10.1097/MLR.0000000000000099.
9
Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD.预测因素、差异和医疗机构间的差异：美国慢性肾脏病退伍军人中 SGLT2 抑制剂的处方情况。
Am J Kidney Dis. 2023 Jul;82(1):53-62.e1. doi: 10.1053/j.ajkd.2022.11.017. Epub 2023 Jan 23.
10
Geographic and Racial/Ethnic Variation in Glycemic Control and Treatment in a National Sample of Veterans With Diabetes.在全国退伍军人糖尿病样本中，血糖控制和治疗的地理和种族/民族差异。
Diabetes Care. 2020 Oct;43(10):2460-2468. doi: 10.2337/dc20-0514. Epub 2020 Aug 7.
引用本文的文献
1
Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes.克服在使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对有和没有2型糖尿病的人群进行心肾保护方面的差异。
J Clin Endocrinol Metab. 2025 Aug 7;110(9):e2852-e2863. doi: 10.1210/clinem/dgaf301.
2
Achieving equitable access to incretin-based therapies in cardiovascular care.在心血管护理中实现对基于肠促胰岛素疗法的公平获取。
Am Heart J Plus. 2024 Sep 10;46:100455. doi: 10.1016/j.ahjo.2024.100455. eCollection 2024 Oct.
3
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD.慢性肾脏病患者停用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂的情况
J Am Soc Nephrol. 2025 Jan 1;36(1):87-98. doi: 10.1681/ASN.0000000000000477. Epub 2024 Aug 26.
本文引用的文献
1
Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD.预测因素、差异和医疗机构间的差异：美国慢性肾脏病退伍军人中 SGLT2 抑制剂的处方情况。
Am J Kidney Dis. 2023 Jul;82(1):53-62.e1. doi: 10.1053/j.ajkd.2022.11.017. Epub 2023 Jan 23.
2
Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States.美国医疗保险覆盖的慢性肾脏病成年患者中，钠-葡萄糖协同转运蛋白2抑制剂或胰高血糖素样肽1受体激动剂起始治疗的差异
Kidney Med. 2022 Oct 31;5(1):100564. doi: 10.1016/j.xkme.2022.100564. eCollection 2023 Jan.
3
Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.2 型糖尿病合并慢性肾脏病患者的心血管和肾脏保护治疗的处方模式。
Diabetes Care. 2022 Dec 1;45(12):2900-2906. doi: 10.2337/dc22-0614.
4
Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.在美国退伍军人事务部医疗体系中，2 型糖尿病患者种族和民族与 SGLT2 抑制剂和 GLP1 受体激动剂处方的相关性。
JAMA. 2022 Sep 6;328(9):861-871. doi: 10.1001/jama.2022.13885.
5
Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.在美国糖尿病患者中，胰高血糖素样肽-1 受体激动剂使用的种族、民族和社会经济不平等现象。
JAMA Health Forum. 2021 Dec 17;2(12):e214182. doi: 10.1001/jamahealthforum.2021.4182. eCollection 2021 Dec.
6
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.KDIGO 2020慢性肾脏病糖尿病管理临床实践指南
Kidney Int. 2020 Oct;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019.
7
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2019美国心脏病学会/美国心脏协会心血管疾病一级预防指南：美国心脏病学会/美国心脏协会临床实践指南工作组报告
Circulation. 2019 Sep 10;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678. Epub 2019 Mar 17.
Zotero 插件